JAMA Neurol: Rituxixim treatment of new systemic severe muscle weakness

Recently, researchers evaluated the efficacy of rituximamono therapy for incurable and new systemic severe muscle weakness, and compared it with conventional immunotherapythis study, for a retrospective cohort study, prospectively collected patient data from Caroline University Hospital in Stockholm, Sweden, including 72 patients with severe muscle weakness who were randomly treated with low doses of rituxima (usually 500 mg every 6 months) or conventional immunosuppressantsThe study looked at the time of remission (main result) as well as the use of rescue therapy or additional immunotherapy and remission time (secondary results)of the 72 patients, 31 (43%) were female, and the average age (SD) at the beginning of treatment was 60 (18)Twenty-four patients received rituxima monoantigen treatment within 12 months of the onset of the disease, and a total of 48 patients received rituxixima treatment, of which 34 had a refractory diseaseA total of 26 patients (3 women , 3The median remission time for patients with relatively difficult diseases was shorter (7 months vs 16 months: risk ratio of HR, 2.53), and the median treatment remission time was shorter compared to conventional immunosuppressants (7 months vs 11 months: HR: 2.97)In addition, the lituxia group required fewer resuscitation treatments in the first 24 months (average sD,0.38,1.10) vs1.31 (1.59) times; average difference: -1.26), and more patients had little or no additional immunotherapy (70% vs35%; OR:5.47)The rate of discontinuation due to adverse events was lower (3% vs46%)of rituxima and conventional therapy compared to conventional therapystudies, the clinical efficacy of rituximamono treatment of new systemic severe muscle weakness is significantly better than conventional immunosuppressants